Stock Data
$1.33 (5.64%)
Asset Type
Common Stock
Exchange
NASDAQ
Currency
USD
Country
USA
Sector
HEALTHCARE
Industry
DIAGNOSTICS & RESEARCH
Adaptive Biotechnologies Corp is at the forefront of harnessing the power of the immune system to improve disease diagnosis and treatment. With a focus on immune medicine, the company's innovative platform offers deep insights into the adaptive immune system, aiding in the development of clinical immunomics data. Its notable product, the clonoSEQ diagnostic test, plays a crucial role in detecting and monitoring cancer cells post-treatment. Adaptive Biotechnologies also engages in significant partnerships, including with Genentech and Microsoft, to advance its mission of transforming disease detection and therapy.
Adaptive Biotechnologies crushed revenue expectations with a 9.3% beat, powered by 43% growth in clonoSEQ test volume, while the EPS miss came entirely from a $23.7 million one-time charge tied to extinguishing a revenue interest liability. The genomics company also raised full-year MRD revenue guidance to $268-$278 million and announced plans to separate its MRD and Immune Medicine businesses into distinct entities.
8 Articles
Our top personal finance-related articles today. Your wallet will thank you later.
